Glenmark Pharma gains on receiving ANDA approval for Teriflunomide Tablets

16 Nov 2018 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 669.45, up by 5.00 points or 0.75% from its previous closing of Rs. 664.45 on the BSE.

The scrip opened at Rs. 671.00 and has touched a high and low of Rs. 674.45 and Rs. 667.10 respectively. So far 7060 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.

Last one week high and low of the scrip stood at Rs. 688.00 and Rs. 643.00 respectively. The current market cap of the company is Rs. 18748.66 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 38.19% and 15.28% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Teriflunomide Tablets, 7 mg and 14 mg, a generic version of Aubagio Tablets, 7 mg and 14 mg, of Sanofi-Aventis U.S., LLC.

With respect to 180-day generic drug exclusivity, the company was one of the first ANDA applicants to submit a substantially complete ANDA for Teriflunomide Tablets, 7 mg and 14 mg, with a paragraph IV certification. Therefore, with this approval, the company is eligible for 180 days of shared generic drug exclusivity for Teriflunomide Tablets, 7 mg and 14 mg. According to IQVIA sales data for the 12 month period ending September 2018, the Aubagio Tablets, 7 mg and 14 mg market achieved annual sales of approximately $1.6 billion.

The company’s current portfolio consists of 142 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×